25
Mar
2026
Watch
Implementation of the Urban Wastewater Treatment Directive (UWWTD) and risks to the security of supply of medicines (debate)
Madam President, Commissioner, it is a pleasure to see you here again. We have been discussing the implementation of the Urban Waste Water Treatment Directive for several months and we always come to the same conclusion: there are more than reasonable doubts about the estimation of costs for each sector. I agree that the objectives of the Directive are legitimate and that the ‘polluter pays’ principle should be followed, in line with the extended producer responsibility scheme. However, it is being asked that pharmaceutical and cosmetic companies have to deal with 80% of quaternary treatment and wastewater, being able to reach 100%. I was delighted to hear you in your opening statement, Commissioner. You are right in what you have said: the figures are too high, and we are concerned that the quality of the estimates used for their calculation is not adequate. We wonder what corresponds to other companies and their co-responsibility in part of the substances that are in the wastewater. Commissioner, we need a comprehensive impact assessment at product level, capable of correctly analysing cost estimates and taking into account the impact on sectors. The European Union cannot afford to jeopardise the availability, affordability and supply of these products, particularly with regard to generic medicines, which none of Europe's citizens cannot miss because they are the ones who cure most of the population. Commissioner, we must not play with the health of our citizens.